

NCI Director's Report

NCI Council of Research Advocates

Norman E. Sharpless, M.D.

June 16, 2021


@NCIDirector

@TheNCI

NCI Appropriations

FY 2015 – 2022 (in millions)

21st Century Cures Act - orange
 Childhood Cancer Initiative - green



U.S.-U.K. Bilateral Cancer Summit



Doug Mills/The New York Times

“We will convene the first U.S.-U.K. Bilateral Cancer Summit and bring together researchers, patients, and other stakeholders to share ideas and identify opportunities for collaboration to accelerate advances in lifesaving approaches to cancer, which remains a leading cause of death worldwide.”

- Joint statement issued June 10, 2021

NCI COVID-19 in Cancer Patients Study (NCCAPS)

875

TRIAL SITES
ACTIVATED
IN

50

STATES
+ DC, PUERTO
RICO, AND
CANADA

Special emphasis on
minority,
underserved and
rural communities

Participants
will be
followed for
2 years

1,137
ENROLLED

88 pediatric patients
enrolled

Launched May 21, 2020
Conception to Launch in
6 weeks


Aims to enroll
2,000 patients
across 1,000
sites in U.S.

ASCO 21
ABSTRACTS

#6565
#6566


COVID-19 SeroHub: US seroprevalence trends

April 2020 – February 2021




Impact of COVID-19 pandemic on cancer screening in the US

Breast Cancer Screening (Mammography)




Colorectal Cancer Screening (Colonoscopy and FIT)





Cancer Screening During the Coronavirus Disease-2019 Pandemic: A Perspective From the National Cancer Institute's PROSPR Consortium. Gastroenterology, Volume 160, Issue 4, 999 - 1002

SEER Coverage As of June 2021

-  Core Registries
-  Research Support Registries



Cancer MoonshotSM



Human Tumor Atlas Network Data Portal

Welcome to the HTAN Data Portal!

The Human Tumor Atlas Network (HTAN) is a National Cancer Institute (NCI)-funded Cancer MoonshotSM initiative to construct 3-dimensional atlases of the dynamic cellular, morphological, and molecular features of human cancers as they evolve from precancerous lesions to advanced disease.

Explore the Data

9

Atlases

8

Organs


509

Cases

1260

Biospecimens

Over 50,000 oncology patients reached by an NCI Cancer Center Cessation Initiative (C3I) tobacco treatment program since 2018



Courtesy of Dr. Betsy Rolland, C3I PI. Data through April 15, 2021.




Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer

Andrew N.J. Tutt, M.B., Ch.B., Ph.D., Judy E. Garber, M.D., M.P.H., Bella Kaufman, M.D., Giuseppe Viale, M.D., Debora Fumagalli, M.D., Ph.D., Priya Rastogi, M.D., Richard D. Gelber, Ph.D., Evandro de Azambuja, M.D., Ph.D., Anitra Fielding, M.B., Ch.B., Judith Balmaña, M.D., Ph.D., Susan M. Domchek, M.D., Karen A. Gelmon, M.D., *et al.*, for the OlympiA Clinical Trial Steering Committee and Investigators*

3-year invasive disease-free survival	Placebo 77.1%	3-year distant disease-free survival	Placebo 80.4%
	Olaparib 85.9%		Olaparib 87.5%
<i>Difference: 8.8 percentage points 95% CI: 4.5 to 13.0.</i>		<i>Difference: 7.1 percentage points 95% CI: 3.0 to 11.1</i>	

Proteogenomic and metabolomic characterization of human glioblastoma


- Phosphorylated PTPN11 and PLCG1 represent a signaling hub in RTK-altered tumors
- Four immune GBM subtypes exist, characterized by distinct immune cell populations
- Mesenchymal subtype EMT signature is specific to tumor cells, but not to stroma
- Histone H2B acetylation is enriched in classical GBMs with low macrophage content





Engage with the Childhood Cancer Data Initiative

- Get [email updates](#) from NCI about CCDI
- View the [CCDI presentation](#) from the December 2, 2020 NCI National Cancer Advisory Board and Board of Scientific Counselors meeting
- Read CCDI *Cancer Currents* Blog Posts: [June 2019](#), [July 2019](#), [July 2020](#)
- [Contact CCDI](#) with questions about engagement, ongoing activities, or funding opportunities



CCDI Childhood Cancer Data Platform

CCDI National Childhood Cancer Cohort

CCDI Childhood Molecular Characterization Protocol

Telehealth & Cancer Care Delivery




Notice of Special Interest (NOSI): Telehealth in Cancer Care - NOT-CA-21-043

PAR-21-190: Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional)	October 8, 2021
PAR-21-035: Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)	June 5, 2021
PAR-19-348: Innovative Approaches to Studying Cancer Communication in the New Information Ecosystem (R01 Clinical Trial Optional)	June 9, 2021
PAR-19-350: Innovative Approaches to Studying Cancer Communication in the New Information Ecosystem (R21 Clinical Trial Optional)	June 9, 2021

NCI Equity and Inclusion Program

<p>EQUITY COUNCIL</p>	<p>Chair Ned Sharpless</p> <p>Co-Chair Paulette Gray</p>	<p>Mark Alexander Andrea Apolo Nelvis Castro Bob Croyle</p>	<p>Montse Garcia-Closas Anne Lubenow Ji Luo</p>	<p>Donna Siegle Dinah Singer Sanya Springfield</p>
<p>WORKING GROUP 1 <i>Enhancing Research to Address Cancer Health Disparities</i></p> <p>CO-CHAIRS</p> <p>Jim Doroshow Worta McCaskill-Stevens Tiffany Wallace</p>	<p>WORKING GROUP 2 <i>Ensuring Diversity of Thought and Background in the Cancer Research Workforce</i></p> <p>CO-CHAIRS</p> <p>LeeAnn Bailey Susan McCarthy Glenn Merlino</p>	<p>WORKING GROUP 3 <i>Promoting an Inclusive and Equitable Community at NCI</i></p> <p>CO-CHAIRS</p> <p>Shannon Bell Satish Gopal Paige Green</p>	<p>WORKING GROUP 4 <i>Systematic Tracking and Evaluation of Equity Activities</i></p> <p>CO-CHAIRS</p> <p>Michelle Bennett Doug Lowy</p>	<p>WORKING GROUP 5 <i>Communications and Outreach for Equity Activities</i></p> <p>CO-CHAIRS</p> <p>Peter Garrett Angela Jones Anita Linde</p>


Demographics of NCI R01 Equivalent PIs (FY 2020)



*More than one race, American Indian or Alaska Native, and Native Hawaiian or Other Pacific Islander

Data Source: Data from NIH OER with analysis by NCI Center for Research Strategy. *Method:* Percents rounded to nearest 1%. Percentages are calculated using the number of PIs that have self-reported their race or ethnicity (92% of all PIs). Hispanic may be any race; race categories exclude Hispanic origin.

Demographics of NCI R01 Equivalent PIs (FY 2020)




*More than one race, American Indian or Alaska Native, and Native Hawaiian or Other Pacific Islander

Data Source: Data from NIH OER with analysis by NCI Center for Research Strategy. *Method:* Percents rounded to nearest 1%. Percentages are calculated using the number of PIs that have self-reported their race or ethnicity (92% of all PIs). Hispanic may be any race; race categories exclude Hispanic origin.

Immediate Action: Early Investigator Advancement Program

Goal: To promote the transition of extramural and intramural early career investigators to independent investigators

Program Components



Outcomes for Each Participant

- Complete an R01 grant proposal
- Become part of a group of peers with similar career goals
- Engage with mentors who are established investigators
- Become familiar with job and funding opportunities
- Develop professional and management skills critical to growing a research group

- *20 participants per cohort*
- *1 cohort per year*

CUSP2CT Connecting Underrepresented Populations to Clinical Trials

PURPOSE

To implement and evaluate multi-level and culturally tailored outreach and education interventions with the primary goal to increase referral of racial/ethnic minority populations to NCI-supported clinical trials.


CUSP2CT Network – FY 22- 26

- Data, Evaluation, and Coordinating Center – 1 U24
- Up to 4 U01s

Will enhance clinical trial participation among racial/ethnic minority populations through a partnership of

- **Community Health Educators**
- **Lay Health Advisors**
- **Clinical Trial Coordinators**
- **Referring providers (primary care and oncologists)**

National Cancer Act of 1971 50th Anniversary



Thank you!